Stay updated on BGB-A317 Clinical Trial: Safety, PK, Antitumor Activities
Sign up to get notified when there's something new on the BGB-A317 Clinical Trial: Safety, PK, Antitumor Activities page.

Latest updates to the BGB-A317 Clinical Trial: Safety, PK, Antitumor Activities page
- Check4 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.SummaryDifference0.1%
- Check12 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%
- Check19 days agoChange DetectedThe web page has been updated to include specific drug information for Tislelizumab and has revised location details, including the addition of South Korea and Taiwan locations. The revision number has also been updated to v3.0.0.SummaryDifference5%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.0%
- Check47 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.6%
Stay in the know with updates to BGB-A317 Clinical Trial: Safety, PK, Antitumor Activities
Enter your email address, and we'll notify you when there's something new on the BGB-A317 Clinical Trial: Safety, PK, Antitumor Activities page.